Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy
Brain and Behavior2019Vol. 9(6), pp. e01312–e01312
Citations Over TimeTop 10% of 2019 papers
Alex Molassiotis, Huilin Cheng, Kwun To Leung, Yu Chung Li, Kam Hung Wong, Joseph S. K. Au, Raghav Sundar, Alexandre Chan, Terrence Rong De Ng, Lorna Kwai Ping Suen, Choi Wan Chan, Janelle Yorke, Violeta López
Abstract
This study confirmed the CIPN risk related to certain variables and identified new ones. This knowledge can assist with treatment decisions and patient education.
Related Papers
- → Chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer survivors treated with taxane: a prospective longitudinal study(2020)41 cited
- [Chemotherapy-induced peripheral neuropathy; impact on quality of life].(2014)
- → Response to: ‘Acupuncture for chemotherapy-induced peripheral neuropathy: a randomised controlled pilot study’(2019)
- → Effect of High-Power Laser Therapy on Modified Total Neuropathy Score in Patients with Chemotherapy Induced Peripheral Neuropathy(2020)
- → Chemotherapy-Induced Peripheral Neuropathy and Treatment(2023)